USPTO Art Unit 1641 Prosecution Statistics

Art Unit Information

Art Unit: 1641
Group: 1640
Tech Center: 1600
Total Cases: 10,785
Last Active: October 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19376432ALBUMIN BINDING PROTEINS AND METHODS OF USEOctober 2025February 2026Allow400YesNo
19302936ALLERGY TREATMENTAugust 2025March 2026Allow710YesNo
19263325COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHYJuly 2025February 2026Allow710YesNo
19259911KLRB1 BINDING AGENTS AND METHODS OF USE THEREOFJuly 2025February 2026Allow810YesNo
19256452FCRN/ANTIGEN-BINDING MOLECULES AND METHODS OF USEJuly 2025January 2026Allow620YesNo
17614288COMPOSITION AND METHODS TO TREAT ECTODERMAL DYSPLASIA 2, CLOUSTON TYPEJune 2025March 2026Allow5211YesNo
19245760ALPHA4BETA7 INTEGRIN BINDING PROTEINS AND METHODS OF USEJune 2025December 2025Allow611NoNo
19242307CAPTURE ANTIBODY AND DETECTION ANTIBODY BINDING MMP9 PROTEINJune 2025August 2025Allow200YesNo
19234136ANTI-TRANSFERRIN RECEPTOR ANTIBODY-PMO CONJUGATES FOR INDUCING DMD EXON 44 SKIPPINGJune 2025February 2026Allow820YesNo
19230064METHODS FOR TREATMENT USING ANTI-ALPHA4BETA7 ANTIBODYJune 2025November 2025Allow610YesNo
19222996METHODS FOR TREATMENT USING ANTI-ALPHA4BETA7 ANTIBODYMay 2025November 2025Allow610YesNo
19221422REGIMENS AND METHODS OF TREATING MULTIPLE SCLEROSIS USING OFATUMUMABMay 2025March 2026Allow911YesNo
19213402ANTIGEN BINDING PROTEINSMay 2025December 2025Allow710NoNo
19211910ANTIBODIES AND ANTIBODY FRAGMENTS THAT BIND IGEMay 2025October 2025Allow510NoNo
19198946Subcutaneous Formulations Of Anti-CD38 Antibodies And Their UsesMay 2025January 2026Allow820NoNo
19194986IMMUNOTHERAPEUTIC COMPOSITION FOR PREVENTION OF OBESITY, NONALCOHOLIC FATTY LIVER DISEASE AND HYPERTRIGLYCERIDEMIA, AND METHODS OF USE AND PREPARATION THEREOFApril 2025October 2025Allow611YesNo
19187342IL31-BINDING POLYPEPTIDES AND USES THEREOFApril 2025August 2025Allow400NoNo
19180749ALBUMIN BINDING PROTEINS AND METHODS OF USEApril 2025September 2025Allow510YesNo
19092641PROCESS OF PURIFICATION OF PROTEINMarch 2025December 2025Allow910NoNo
19073405FUS PROTEOLYSIS-TARGETING CHIMERA, PREPARATION METHOD AND APPLICATIONS THEREOFMarch 2025May 2025Allow300NoNo
19074158PLATELET DERIVATIVE COMPOSITIONS, AND PLURALITIES OF CONTAINERS CONTAINING SAMEMarch 2025April 2025Allow200NoNo
19069168FC FRAGMENTS THAT BIND FCRN AND METHODS OF USEMarch 2025January 2026Abandon1011YesNo
19065094ANTIBODIES TO CONNECTIVE TISSUE GROWTH FACTOR (CTGF) AND USES THEREOFFebruary 2025December 2025Allow911YesNo
19061157METHODS OF TREATING INFLAMMATORY AND/OR ALLERGIC DISORDERS WITH NORKETOTIFENFebruary 2025December 2025Abandon911NoNo
19050002ANTI-IgE ANTIBODY THERAPY FOR MULTIPLE FOOD ALLERGIESFebruary 2025July 2025Allow610NoNo
19048808Production of Biosimilar Ustekinumab In CHO CellsFebruary 2025March 2026Allow1321YesNo
19035322N-TERMINAL scFv MULTISPECIFIC BINDING MOLECULESJanuary 2025January 2026Allow1211YesNo
19034098METHODS FOR TREATING FIBRODYSPLASIA OSSIFICANS PROGRESSIVAJanuary 2025July 2025Allow610YesNo
19026296MRNA VACCINE ENCODING FUSION ANTIGEN AGAINST MPOX AND SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2January 2025April 2025Allow300YesNo
19023442ALBUMIN PROTEIN VARIANTS, PRODUCTION THEREOF AND USES OF SAMEJanuary 2025January 2026Allow1221NoNo
19010257ENHANCED PEPTIDE CONSTRUCTS FOR ALBUMIN BINDINGJanuary 2025June 2025Allow610YesNo
18880418DISPLACERS OF IGE-FCERIDecember 2024March 2026Allow1420NoNo
19005584TL1A BINDING PROTEINS AND METHODS OF USEDecember 2024October 2025Allow911YesNo
19003301BISPECIFIC CHIMERIC ANTIGEN RECEPTORS TARGETING CD20 AND BCMADecember 2024April 2025Allow300YesNo
19000524POLYPEPTIDE ANTIGEN OF BOVINE AND SHEEP PREGNANCY-ASSOCIATED GLYCOPROTEIN AND APPLICATION THEREOFDecember 2024August 2025Abandon810NoNo
18988307HUMANIZED ANTIBODIES AGAINST IRHOM2December 2024March 2025Allow300YesNo
18980920FCRN/HSA BINDING MOLECULES AND METHODS OF USEDecember 2024May 2025Allow501NoNo
18977144NOVEL ANTIGEN BINDING MOLECULE FORMATSDecember 2024April 2025Allow410NoNo
18962263ANTI-S100A4 HUMANIZED ANTIBODIES, USES AND METHODSNovember 2024April 2025Allow411NoNo
18951667PREPARATION METHOD AND APPLICATION OF SINGLE-CHAIN ANTIBODY FRAGMENT TARGETING SARS-COV-2 NUCLEOCAPSID PROTEINNovember 2024July 2025Allow820NoNo
18945784Antibodies Targeting ActRIIA and ActRIIBNovember 2024February 2025Allow310NoNo
18938970ANTIBODIES FOR TREATING ALPHA-SYNUCLEINOPATHIESNovember 2024July 2025Allow811NoNo
18934237RNA for In vivo Transfection with Increased ExpressionNovember 2024July 2025Allow911YesNo
18922371METHODS FOR TREATMENT USING ANTI-ALPHA4BETA7 ANTIBODYOctober 2024March 2025Allow510YesNo
18920412ANTI-PHOSPHOCHOLINE ANTIBODIES AND METHODS OF USE THEREOFOctober 2024March 2025Allow501YesNo
18914727ANTI-PD-L1 ANTIBODY, ANTI-PD-1 ANTIBODY, AND THE USE OF INHIBITOR TARGETING PD-1/PD-L1 AND COX-2 INHIBITOROctober 2024August 2025Abandon1011NoNo
18910445ANTI-MUC1* ANTIBODY DRUG COMPLEXES AND USES THEREOFOctober 2024November 2025Abandon1321YesNo
18895539HEPARANASE-NEUTRALIZING A54 MONOCLONAL ANTIBODYSeptember 2024June 2025Allow810YesNo
18850224PEPTIDE USEFUL FOR THE TRANSPORT OF MOLECULES THROUGH CELL BARRIERSSeptember 2024June 2025Allow910NoNo
18892256ANTIBODY-CONJUGATES FOR TARGETING OF TUMOURS EXPRESSING CARCINOEMBYRONIC ANTIGENSeptember 2024December 2025Allow1521YesNo
18892093ANTI-NME ANTIBODY AND METHOD OF TREATING CANCER OR CANCER METASTASISSeptember 2024May 2025Allow720NoNo
18817152PROTEIN S ANTIBODIES, METHODS OF MAKING AND USES THEREOFAugust 2024May 2025Allow911NoNo
18815390FUSION PROTEIN COMPRISING ANTI-CD73 ANTIBODY AND IL-2, AND USE THEREOFAugust 2024May 2025Allow911YesNo
18810381METHODS USING FREEZE-DRIED PLATELET DERIVATIVE COMPOSITIONS FOR RESTORING HEMOSTASIS IN A SUBJECTAugust 2024February 2025Allow611YesNo
18774646COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIESJuly 2024April 2025Allow920YesNo
18774629COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIESJuly 2024March 2025Allow820YesNo
18774608COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIESJuly 2024January 2025Allow610YesNo
18773400VIVO GENE THERAPY USING INTRAOSSEOUS DELIVERY OF A LENTIVIRAL GENE CONSTRUCTJuly 2024June 2025Allow1120YesNo
18770102PHOSPHO-TAU ANTIBODIES AND METHODS OF USEJuly 2024March 2025Allow811YesNo
18764499ENHANCED PEPTIDE CONSTRUCTS FOR ALBUMIN BINDINGJuly 2024May 2025Abandon1011YesNo
18750999PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCERJune 2024June 2025Abandon1201NoNo
18750887PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCERJune 2024June 2025Abandon1201NoNo
18750908PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCERJune 2024April 2025Abandon1010NoNo
18745750ANTI-RECEPTOR EXPRESSED ON LYMPHOID TISSUES (RELT) RECOMBINANT MONOCLONAL ANTIBODY AND PREPARATION METHOD AND USE THEREOFJune 2024November 2024Allow510YesNo
18744084CYTOSTATIC CONJUGATES WITH INTEGRIN LIGANDSJune 2024January 2026Abandon1911NoNo
18739089COMPOSITIONS AND METHODS FOR TREATING SEVERE ASTHMAJune 2024October 2025Abandon1601NoNo
18733287Anti-DLL3 Antibodies and Uses ThereofJune 2024April 2025Allow1101YesNo
18715020Pharmaceutical formulation comprising aqueous solution of antibodyMay 2024July 2025Allow1410NoNo
18677564ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USEMay 2024May 2025Allow1212NoNo
18669092SINGLE-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOFMay 2024September 2025Allow1610NoNo
18664091BINDING AGENTS TARGETING TROP2-EXPRESSING TUMOR CELLSMay 2024December 2024Allow710NoNo
18664070BINDING AGENTS TARGETING TROP2-EXPRESSING TUMOR CELLSMay 2024March 2025Allow1020NoNo
18664201VARIANT NUCLEIC ACID LIBRARIES FOR CORONAVIRUSMay 2024January 2025Allow800YesNo
18659740Particle Formation And MorphologyMay 2024November 2025Allow1831YesNo
18660162MODIFIED IMMUNOGLOBULINS FOR TARGETING AMYLOID DEPOSITSMay 2024January 2025Allow920YesNo
18660156MODIFIED IMMUNOGLOBULINS FOR TARGETING AMYLOID DEPOSITSMay 2024July 2024Allow200NoNo
18654538HUMAN ANTI-SEMAPHORIN 4D ANTIBODYMay 2024October 2025Allow1811NoNo
18646706DNASE FUSION POLYPEPTIDES AND RELATED COMPOSITIONS AND METHODSApril 2024August 2025Abandon1600NoNo
18703646ANTIBODIES TO CORONAVIRUS SARS-COV-2April 2024September 2025Abandon1711NoNo
18640985CONSTRUCTS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) AND USES THEREOFApril 2024July 2025Abandon1501NoNo
18640981NOVEL ANTIGEN BINDING MOLECULE FORMATSApril 2024February 2025Allow1011YesNo
18627754Anti-SIRPa Antibodies and Methods of Use ThereofApril 2024November 2024Allow700NoNo
18610978ANTIBODIES TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOFMarch 2024March 2026Abandon2421NoNo
18609108MULTISPECIFIC BINDING CONSTRUCTS AGAINST CHECKPOINT MOLECULES AND USES THEREOFMarch 2024August 2025Allow1710NoNo
18607180ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN AND USE THEREOFMarch 2024August 2024Allow510NoNo
18607194INTERFERON ALPHA-2 VARIANTSMarch 2024July 2025Allow1621NoNo
18601952ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN yC DOMAIN AND METHODS OF USEMarch 2024December 2024Allow920NoNo
18601222ANTIBODIES RECOGNIZING TAUMarch 2024July 2025Allow1720YesNo
18599751PHOSPHO-TAU ANTIBODIES AND METHODS OF USEMarch 2024February 2025Allow1110YesNo
18599591Method for Delivering Drug to MuscleMarch 2024January 2026Abandon2220NoNo
18598342ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOFMarch 2024August 2024Allow610NoNo
18597624REGIMENS AND METHODS OF TREATING MULTIPLE SCLEROSIS USING OFATUMUMABMarch 2024February 2025Allow1111YesNo
18588667COMPOSITIONS AND METHODS OF TREATING SARCOMA LUNG METASTASISFebruary 2024May 2025Abandon1510NoNo
18585676COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATESFebruary 2024April 2025Allow1421YesNo
18444471COMPOSITIONS COMPRISING PHARMACEUTICALLY ACCEPTABLE SALTS OF AMYLIN ANALOGS AND USES THEREOFFebruary 2024November 2024Allow911YesNo
18442779CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODSFebruary 2024June 2025Allow1610NoNo
18440895Fc VARIANTS WITH ALTERED BINDING TO FcRnFebruary 2024June 2024Abandon400NoNo
18440437SPECIFIC BINDING MOLECULESFebruary 2024March 2025Allow1310NoNo
18439344Nano-sized Chitosan/VS2 nanocomposite like flowers for Antimicrobial ApplicationsFebruary 2024November 2024Allow911YesNo
18439336Method for Making Nano-sized Chitosan/VS2 NanocompositesFebruary 2024October 2024Allow820NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1641.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
204
Examiner Affirmed
137
(67.2%)
Examiner Reversed
67
(32.8%)
Reversal Percentile
51.8%
Higher than average

What This Means

With a 32.8% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
1226
Allowed After Appeal Filing
288
(23.5%)
Not Allowed After Appeal Filing
938
(76.5%)
Filing Benefit Percentile
13.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 23.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1641 - Prosecution Statistics Summary

Executive Summary

Art Unit 1641 is part of Group 1640 in Technology Center 1600. This art unit has examined 10,785 patent applications in our dataset, with an overall allowance rate of 54.9%. Applications typically reach final disposition in approximately 38 months.

Comparative Analysis

Art Unit 1641's allowance rate of 54.9% places it in the 11% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1641 receive an average of 2.09 office actions before reaching final disposition (in the 67% percentile). The median prosecution time is 38 months (in the 18% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.